• 1. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 2. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 3. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 4. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 5. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Thiazolecarboxylic acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Thiazoles Thiazolecarboxylic acids and derivatives

Introduction to 2-Thiazolecarboxylic acid, 5-(bromomethyl) (CAS No. 1823420-00-3)

2-Thiazolecarboxylic acid, 5-(bromomethyl), identified by the Chemical Abstracts Service Number (CAS No.) 1823420-00-3, is a significant compound in the realm of pharmaceutical and biochemical research. This heterocyclic organic compound belongs to the thiazole family, characterized by a sulfur atom and a nitrogen atom in its five-membered ring structure. The presence of a bromomethyl substituent at the 5-position enhances its reactivity, making it a valuable intermediate in synthetic chemistry and drug development.

The thiazole core is a privileged scaffold in medicinal chemistry due to its broad biological activity and structural versatility. Thiazole derivatives have been extensively studied for their potential applications in antimicrobial, antiviral, anti-inflammatory, and anticancer therapies. The introduction of a bromomethyl group at the 5-position of thiazole increases its utility as a building block for more complex molecules. This modification allows for further functionalization via nucleophilic substitution reactions, enabling the synthesis of diverse pharmacophores.

In recent years, there has been growing interest in thiazole derivatives as lead compounds for novel therapeutic agents. The 5-(bromomethyl)thiazole-2-carboxylic acid derivative has emerged as a promising candidate in several preclinical studies. Its ability to interact with biological targets such as enzymes and receptors makes it an attractive scaffold for drug design. Researchers have explored its potential in inhibiting key enzymes involved in cancer progression, such as kinases and proteases.

One of the most compelling aspects of 2-Thiazolecarboxylic acid, 5-(bromomethyl) is its role in the development of targeted therapies. The bromomethyl group facilitates the attachment of other bioactive molecules, allowing for the creation of conjugates that can selectively target specific disease pathways. For instance, studies have demonstrated its utility in designing small-molecule inhibitors that disrupt tumor microenvironments by modulating signaling pathways critical for cancer cell survival and proliferation.

The synthetic accessibility of this compound also contributes to its appeal in pharmaceutical research. It can be readily synthesized through established methods, such as bromination of thiazole-2-carboxylic acid derivatives or condensation reactions involving bromomethylating agents. This ease of preparation allows researchers to explore its pharmacological properties without significant synthetic challenges.

Recent advancements in computational chemistry have further enhanced the understanding of 2-Thiazolecarboxylic acid, 5-(bromomethyl)'s interactions with biological targets. Molecular docking studies have revealed that this compound can bind to various proteins with high affinity, suggesting multiple potential therapeutic applications. These virtual screening approaches have identified novel analogs with improved efficacy and reduced toxicity compared to existing drugs.

The pharmacokinetic profile of thiazole derivatives is another area of active investigation. The structural features of 5-(bromomethyl)thiazole-2-carboxylic acid influence its absorption, distribution, metabolism, and excretion (ADME) properties. Optimization of these parameters is crucial for developing drugs that exhibit favorable bioavailability and minimal side effects. Preclinical data indicate that this compound exhibits reasonable solubility and stability under physiological conditions, making it suitable for further development.

In conclusion, 2-Thiazolecarboxylic acid, 5-(bromomethyl) (CAS No. 1823420-00-3) represents a versatile and promising scaffold for pharmaceutical innovation. Its unique structural features and reactivity make it an invaluable tool for drug discovery efforts aimed at addressing various diseases. As research continues to uncover new applications for this compound, it is likely to play an increasingly important role in the development of next-generation therapeutics.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)